🇺🇸 NuTRIflex Lipid peri in United States

32 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 32

Most-reported reactions

1. Abdominal Pain Upper — 4 reports (12.5%)
2. Diarrhoea — 4 reports (12.5%)
3. Fatigue — 4 reports (12.5%)
4. Testicular Pain — 4 reports (12.5%)
5. General Physical Health Deterioration — 3 reports (9.38%)
6. Hyperhidrosis — 3 reports (9.38%)
7. Pyrexia — 3 reports (9.38%)
8. Sepsis — 3 reports (9.38%)
9. Abdominal Pain — 2 reports (6.25%)
10. Febrile Neutropenia — 2 reports (6.25%)

Source database →

Frequently asked questions

Is NuTRIflex Lipid peri approved in United States?

NuTRIflex Lipid peri does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for NuTRIflex Lipid peri in United States?

B. Braun Melsungen AG is the originator. The local marketing authorisation holder may differ — check the official source linked above.